Worachet Kuntawunginn

Mr. Worachet Kuntawunginn


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
PVPattaraporn Vanachayangkul
Pattaraporn Vanachayangkul
CLChanthap Lon
Chanthap Lon
MSMichele Spring
Michele Spring
SSSommethy Sok
Sommethy Sok
WTWinita Ta-Aksorn
Winita Ta-Aksorn
DSDavid Saunders
David Saunders
Despite the rising rates of resistance to dihydroartemisinin-piperaquine (DP), DP remains a first-line therapy for uncomplicated malaria in many parts of Cambodia. While DP is generally well tolerated as a 3-day DP (3DP) regimen, compressed 2-day DP (2DP) regimens were associated with treatment-limiting cardiac repolarization effects in a recent clinical trial. To better estimate the risks of piperaquine on QT interval prolongation, we pooled data from three randomized clinical trials conducted between 2010 and 2014 in northern Cambodia. A population pharmacokinetic model was developed to compare exposure-response relationships between the 2DP and 3DP regimens while accounting for differences in regimen and sample collection times between studies. A 2-compartment model with first-order absorption and elimination without covariates best fit the data. The linear slope-intercept model predicted a 0.05-ms QT prolongation per ng/ml of piperaquine (5 ms per 100 ng/ml) in this largely male population. Though the plasma half-life was similar in both regimens, peak and total piperaquine exposures were higher in those treated with the 2DP regimen. Furthermore, the correlation between the plasma piperaquine concentration and the QT interval prolongation was stronger in the population receiving the 2DP regimen. Neither the time since the previous meal nor the baseline serum magnesium or potassium levels had additive effects on QT interval prolongation. As electrocardiographic monitoring is often nonexistent in areas where malaria is endemic, 2DP regimens should be avoided and the 3DP regimen should be carefully considered in settings where viable alternative therapies exist. When DP is employed, the risk of cardiotoxicity can be mitigated by combining a 3-day regimen, enforcing a 3-h fast before and after administration, and avoiding the concomitant use of QT interval-prolonging medications. (This study used data from three clinical trials that are registered at ClinicalTrials.gov under identifiers NCT01280162, NCT01624337, and NCT01849640.)

5 August 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
MSMichele Spring
Michele Spring
CLChanthap Lon
Chanthap Lon
SSSomethy Sok
Somethy Sok
DSDarapiseth Sea
Darapiseth Sea
MWMariusz Wojnarski
Mariusz Wojnarski
NWNorman C. Waters
Norman C. Waters
Clinical failure of primaquine (PQ) has been demonstrated in people with CYP450 2D6 genetic polymorphisms that result in reduced or no enzyme activity. The distribution of CYP2D6 genotypes and predicted phenotypes in the Cambodian population is not well described. Surveys in other Asian countries have shown an approximate 50% prevalence of the reduced activity of the CYP2D6 allele *10, which could translate into increased risk of PQ radical cure failure and repeated relapses, making interruption of transmission and malaria elimination difficult to achieve. We determined CYP2D6 genotypes from 96 volunteers from Oddor Meanchey Province, Cambodia, an area endemic for Plasmodium vivax. We found a 54.2% frequency of the *10 allele, but in approximately half of our subjects, it was paired with a normal activity allele, either *1 or *2. The prevalence of *5, a null allele, was 9.4%. Overall predicted phenotype percentages were normal metabolizers, 46%; intermediate metabolizers, 52%; and poor metabolizers, 1%.

2 December 2015 in Malaria Journal
Verified
Journal Article
Open access
PDF file
SCSuwanna Chaorattanakawee
Suwanna Chaorattanakawee
CLCharlotte A. Lanteri
Charlotte A. Lanteri
SSSiratchana Sundrakes
Siratchana Sundrakes
KYKritsanai Yingyuen
Kritsanai Yingyuen
PGPanita Gosi
Panita Gosi
DSDavid L. Saunders
David L. Saunders
There is currently no standardized approach for assessing in vitro anti-malarial drug susceptibility. Potential alterations in drug susceptibility results between fresh immediate ex vivo (IEV) and cryopreserved culture-adapted (CCA) Plasmodium falciparum isolates, as well as changes in parasite genotype during culture adaptation were investigated. The 50 % inhibitory concentration (IC50) of 12 P. falciparum isolates from Cambodia against a panel of commonly used drugs were compared using both IEV and CCA. Results were compared using both histidine-rich protein-2 ELISA (HRP-2) and SYBR-Green I fluorescence methods. Molecular genotyping and amplicon deep sequencing were also used to compare multiplicity of infection and genetic polymophisms in fresh versus culture-adapted isolates. IC50 for culture-adapted specimens were significantly lower compared to the original fresh isolates for both HRP-2 and SYBR-Green I assays, with greater than a 50 % decline for the majority of drug-assay combinations. There were correlations between IC50s from IEV and CCA for most drugs assays. Infections were nearly all monoclonal, with little or no change in merozoite surface protein 1 (MSP1), MSP2, glutamate-rich protein (GLURP) or apical membrane antigen 1 (AMA1) polymorphisms, nor differences in P. falciparum multidrug resistance 1 gene (PfMDR1) copy number or single nucleotide polymorphisms following culture adaptation. The overall IC50 reduction combined with the correlation between fresh isolates and culture-adapted drug susceptibility assays suggests the utility of both approaches, as long as there is consistency of method, and remaining mindful of possible attenuation of resistance phenotype occurring in culture. Further study should be done in higher transmission settings where polyclonal infections are prevalent.

Verified
Journal Article
Open access
PDF file
PBParat Boonyarangka
Parat Boonyarangka
KPKittijarankon Phontham
Kittijarankon Phontham
SSSabaithip Sriwichai
Sabaithip Sriwichai
KPKamonporn Poramathikul
Kamonporn Poramathikul
KHKrit Harncharoenkul
Krit Harncharoenkul
MSMichele Spring
Michele Spring
With the emergence of SARS-CoV-2, healthcare systems not only had to address the pressing clinical needs of the COVID-19 pandemic but anticipate the effect on and of other conditions and diseases. This was of particular concern in areas of the world endemic with malaria, a disease which takes hundreds of thousands of lives each year. This case report from Thailand describes a 25-year-old man diagnosed with Plasmodium vivax, who was then found to be co-infected with COVID-19. Both conditions can have overlapping acute febrile illness symptoms which may delay or complicate diagnoses. He had no prior history of malaria and had received two vaccinations against COVID-19. His clinical course was mild with no pulmonary complications or oxygen requirement, and he responded well to treatments for both conditions. Three months after cure, he again contracted COVID-19 but did not experience any P. vivax relapse. Review of the available literature produced less than 10 publications describing co-infections with P. vivax and COVID-19; nonetheless, in endemic areas, vigilance for both diseases should continue, as co-infections could significantly alter the course of clinical management and prognosis as well as affect the healthcare staff caring for these patients.

16 October 2018 in Trials
Verified
Journal Article
Open access
PDF file
JMJessica Manning
Jessica Manning
CLChanthap Lon
Chanthap Lon
MSMichele Spring
Michele Spring
MWMariusz Wojnarski
Mariusz Wojnarski
SSSok Somethy
Sok Somethy
DSDavid Saunders
David Saunders
Malaria remains a critical public health problem in Southeast Asia despite intensive containment efforts. The continued spread of multi-drug-resistant Plasmodium falciparum has led to calls for malaria elimination on the Thai-Cambodian border. However, the optimal approach to elimination in difficult-to-reach border populations, such as the Military, remains unclear. A two-arm, cluster-randomized controlled, open-label pilot study is being conducted in military personnel and their families at focal endemic areas on the Thai-Cambodian border. The primary objective is to compare the effectiveness of monthly malaria prophylaxis (MMP) with dihydroartemisinin-piperaquine and weekly primaquine for 12 weeks compared with focused screening and treating (FSAT) following current Cambodian national treatment guidelines. Eight separate military encampments, making up approximately 1000 military personnel and their families, undergo randomization to the MMP or FSAT intervention for 3 months, with an additional 3 months’ follow-up. In addition, each treatment cluster of military personnel and civilians is also randomly assigned to receive either permethrin- or sham (water)-treated clothing in single-blind fashion. The primary endpoint is risk reduction for malaria infection in geographically distinct military encampments based on their treatment strategy. Monthly malaria screening in both arms is done via microscopy, PCR, and rapid diagnostic testing to compare both the accuracy and cost-effectiveness of diagnostic modalities to detect asymptomatic infection. Universal glucose-6-phosphate dehydrogenase (G6PD) deficiency screening is done at entry, comparing the results from a commercially available rapid diagnostic test, the fluorescence spot test, and quantitative testing for accuracy and cost-effectiveness. The comparative safety of the interventions chosen is also being evaluated. Despite the apparent urgency, the key operational elements of proposed malaria elimination strategies in Southeast Asian mobile and migrant populations, including the Military, have yet to be rigorously tested in a well-controlled clinical study. Here, we present a protocol for the primary evaluation of two treatment paradigms – monthly malaria prophylaxis and focused screening and treatment – to achieve malaria elimination in a Cambodian military population. We will also assess the feasibility and incremental benefit of outdoor-biting vector intervention – permethrin-treated clothing. In the process, we aim to define the cost-effectiveness of the inputs required for success including a responsive information system, skilled human resource and laboratory infrastructure requirements, and quality management. Despite being a relatively low transmission area, the complexities of multi-drug-resistant malaria and the movement of vulnerable populations require an approach that is not only technically sound, but simple enough to be achievable. ClinicalTrials.gov, ID: NCT02653898 . Registered on 13 January 2016.

Verified
Journal Article
Open access
PDF file
PBParat Boonyarangka
Parat Boonyarangka
PSPheutsapha Sonthilath
Pheutsapha Sonthilath
SCSidhartha Chaudhury
Sidhartha Chaudhury
VBVirasack Banouvong
Virasack Banouvong
WKWorachet Kuntawunginn
Worachet Kuntawunginn
KJKrisada Jongsakul
Krisada Jongsakul
While vector control methods have successfully reduced malaria rates worldwide, such methods are not always suitable for military use. We evaluated the usability, durability, and effectiveness of permethrin-treated uniforms and metofluthrin spatial repellent in preventing mosquito bites among soldiers in the Laos People’s Army that were deployed on a 12-week field exercise. The study enrolled 173 subjects into four different groups: (1) metofluthrin-only, (2) permethrin-treated uniforms, (3) metofluthrin with permethrin-treated uniforms, and (4) a control group. We measured efficacy through self-reported survey responses and a serological test for antibodies to Anopheles salivary antigens and assessed the durability of permethrin treatment over the 12-week exercise. We found that soldiers given metofluthrin and permethrin-treated uniforms were 72% and 46% more likely to report decreased mosquito bites compared to those in the control group and that soldiers with permethrin-treated uniforms had significantly lower (p < 0.05) antibody levels to the Anopheles SG6 salivary antigen. Mass spectrometry analysis revealed that treated uniforms still contained a significant permethrin concentration that showed 50 to 100% mosquito mortality. Overall, our findings show that both metofluthrin and permethrin-treated uniforms were well-tolerated and led to significantly fewer reported mosquito bites, and that permethrin, in particular, was found to be durable throughout the 12-week field exercise and effective in reducing mosquito bite exposure, underscoring its value in military applications.